Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis serogroup C disease

A bivalent factor H binding protein (fHBP) vaccine for the prevention of disease caused by Neisseria meningitidis serogroup B is currently in clinical development. Since fHBP is also expressed by other meningococcal serogroups, antifHBP antibodies may have bactericidal activity against meningococci...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Harris, Shannon L, Zhu, Duzhang, Murphy, Ellen, McNeil, Lisa K, Wang, Xin, Mayer, Leonard W, Harrison, Lee H, Jansen, Kathrin U, Anderson, Annaliesa S
Formato: Artigo
Lenguaje:Inglês
Publicado: Landes Bioscience 2011
Materias:
Review
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3367671/
https://ncbi.nlm.nih.gov/pubmed/21245657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.7.0.14564
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares